Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada

BACKGROUND: Use of costly biologic drugs for the treatment of chronic inflammatory diseases has increased significantly in recent years. However, biosimilar drugs offer an opportunity to ensure health system sustainability with robust uptake. OBJECTIVE: To study the effect of formulary listing strat...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenna, Jennifer, McCormack, Daniel, Kitchen, Sophie, Martins, Diana, Gomes, Tara, Tadrous, Mina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391289/
https://www.ncbi.nlm.nih.gov/pubmed/33769851
http://dx.doi.org/10.18553/jmcp.2021.27.4.444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391289/
https://www.ncbi.nlm.nih.gov/pubmed/33769851
http://dx.doi.org/10.18553/jmcp.2021.27.4.444

Ejemplares similares